Scarica l'app Stockscreener
147.01
7.86%
10.71
Dopo l'orario di chiusura:
146.65
-0.36
-0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Investors Purchase High Volume of Revolution Medicines Call Options (NASDAQ:RVMD) - MarketBeat
RVMD Maintains by RBC Capital -- Price Target Raised to $162 - GuruFocus
RVMD Maintained by Wells Fargo -- Price Target Raised to $167 - GuruFocus
Revolution Medicines (NASDAQ:RVMD) Given New $167.00 Price Target at Wells Fargo & Company - MarketBeat
Revolution Medicines Stock Soars on Breakthrough Cancer Data - TipRanks
RVMD Maintained by Evercore ISI Group -- Price Target Raised to $200 - GuruFocus
RVMD Reiterated by Wedbush -- Price Target Maintained at $147.00 - GuruFocus
RVMD Maintained by Guggenheim -- Price Target Raised to $175 - GuruFocus
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report) - FinancialContent
Why Did Oncology Stock Revolution Medicines (RVMD) Gain 41% Monday? - Investorideas.com
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
RVMD Maintained by HC Wainwright & Co. -- Price Target Raised to $169 - GuruFocus
RBC Raises Price Target on Revolution Medicines to $162 From $140, Keeps Outperform, Speculative Risk - marketscreener.com
H.C. Wainwright raises Revolution Medicines price target to $169 - Investing.com
Pancreatic cancer pill shown to nearly double overall survival time, drug company says - The Hill
H.C. Wainwright raises Revolution Medicines price target to $169 By Investing.com - Investing.com Canada
Revolution Medicines (RVMD) Is Up 42.9% After Phase 3 Daraxonrasib Survival Data And $750M Equity Raise – Has The Bull Case Changed? - Yahoo Finance
Revolution Medicines Doubles Pancreatic Cancer Survival in Phase 3 Trial — Is RVMD Stock a Buy at $136? - TradingKey
Baillie Gifford & Co. Invests $15.53 Million in Revolution Medicines, Inc. $RVMD - MarketBeat
US biotech seeks quick FDA approval after improved survivability with cancer candidate - medwatch.com
Revolution Medicines Stock Surges After Trial Data: Is Biotech Back? - EBC Financial Group
Revolution Medicines (RVMD) Sees Potential Surge Following Phase III Trial Success - GuruFocus
Revolution Medicines (RVMD) Soars to All-Time High on Stellar Cancer Treatment Trial - Insider Monkey
Revolution Medicines (RVMD) Plans $1 Billion in Offerings to Bol - GuruFocus
Revolution’s daraxonrasib nails endpoints in pancreatic cancer trial - BioWorld News
Revolution Medicines plans $1 billion dual offering By Investing.com - Investing.com India
RVMD Stock Jumps As Analysts Hike Price Targets On Pancreatic Cancer Bets - timothysykes.com
Revolution Medicines shares pop after pancreatic cancer drug trial win - CNBC
Revolution Medicines shares jump on breakthrough pancreatic cancer trial results - MSN
Revolution Medicines, Inc. Announces Proposed Offerings Of Common Stock And Convertible Senior Notes - TradingView — Track All Markets
Revolution Medicines plans $1B combined equity and convertible note offerings - MSN
Revolution Medicines (RVMD) files $750M share sale; $250M convertible notes planned - Stock Titan
Revolution Medicines (NASDAQ: RVMD) seeks $250M via convertible notes, concurrent $750M stock sale - Stock Titan
Revolution Medicines plans $1 billion dual offering - Investing.com
Top Biotech Catapults On 'Unprecedented' Results In Cancer - Investor's Business Daily
Revolution Medicines Announces Unprecedented Survival Gains with Daraxonrasib in Late-Stage Pancreatic Cancer Study - BBN Times
U.S. Markets Rose Monday; Revolution Medicines Topped Leaders - Barron's
Leerink Partners Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $147.00 - MarketBeat
Revolution Medicines seeks $1B to fund cancer-drug R&D, launch prep - Stock Titan
Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial - MedCity News
Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy? - Barchart.com
Revolution Medicines stock hits all-time high at 132.41 USD By Investing.com - Investing.com Australia
RVMD Stock Rallies As Analysts Hike Price Targets On Trial Momentum - timothysykes.com
RVMD Maintained by Oppenheimer -- Price Target Raised to $165 - GuruFocus
Revolution Medicines (RVMD) Stock Surges 38.7% - GuruFocus
Revolution Medicines surges 38% on pancreatic cancer breakthrough - CryptoRank
Revolution Medicines Announces Breakthrough in Pancreatic Cancer Treatment with daraxonrasib - GuruFocus
Revolution Medicines (RVMD) Sees Remarkable 37.9% Surge - GuruFocus
Revolution Medicines: PDAC Data Wows Wall StreetJury's Out On Further Upside (RVMD) - Seeking Alpha
RVMD Stock Jumps As Analysts Hike Targets On Trial Hopes - StocksToTrade
Revolution Medicines reports positive Phase 3 results for daraxonrasib in pancreatic cancer By Investing.com - Investing.com India
Revolution Medicines (RVMD) Soars After Positive Cancer Drug Tri - GuruFocus
Revolution Medicines (RVMD) Hits All-Time Highs After Groundbreaking Cancer Trial Results - GuruFocus
Revolution Medicines (RVMD) Achieves Significant Clinical Trial Results - GuruFocus
Revolution Medicines price target raised to $165 from $150 at Oppenheimer - TipRanks
Revolution Medicines catapults 30%-plus on upbeat results for pancreatic cancer drug - MSN
BofA raises Revolution stock price target to $170 on drug outlook - Investing.com
Revolution Medicines (RVMD) Surges 36% After Positive Phase 3 Tr - GuruFocus
Revolution Medicines (NASDAQ:RVMD) Hits New 52-Week HighHere's Why - MarketBeat
Leerink raises Revolution stock price target on trial success By Investing.com - Investing.com Australia
RVMD Stock Extends Run As Analysts Hike Price Targets - timothysykes.com
Revolution Medicines' daraxonrasib shows unprecedented overall survival - The Pharma Letter
Raymond James raises Revolution Medicines price target on trial win By Investing.com - Investing.com South Africa
Major Breakthrough in Pancreatic Cancer Treatment: Revolution Medicines' Targeted Drug Succeeds in Phase III Trial, Nearly Doubling Patient Survival - 富途牛牛
Why Did Revolution Medicines (RVMD) Stock Soar Today? - TipRanks
Revolution Medicines (RVMD) Stock Jumps 38% Following Breakthrough Pancreatic Cancer Data - MEXC
Revolution Medicines (RVMD) Exceeds Expectations in Pancreatic C - GuruFocus
1.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):